Semax and Selank: Two Compounds, Different Research Questions

Two peptide names, not one mechanism

Semax and Selank are often grouped under cognitive research, but that label hides important differences. Their molecular designs have different starting points, and the human studies discussed here ask different questions. A change in brain-network connectivity, a change on an anxiety rating scale and an improvement in memory are not interchangeable findings.

Both compounds are synthetic heptapeptides: molecules made from seven linked amino-acid residues. Semax combines an ACTH-derived sequence with a Pro-Gly-Pro extension. Selank combines the sequence of tuftsin, a four-residue peptide, with Pro-Gly-Pro. Sharing that extension does not make their complete structures or biological effects equivalent. Nor does a relationship to a naturally occurring peptide establish that a synthetic analogue reproduces all of its actions.

What a Semax brain scan can reveal

A 2018 study examined 24 healthy volunteers, with 14 receiving intranasal 1% Semax and 10 receiving placebo. Participants had a mean age of 43.9 ± 9.5 years. Resting-state functional MRI was performed before administration and at five and twenty minutes afterward. The investigators examined connectivity within the default mode network, a set of brain regions commonly studied during wakeful rest. Primary study, PMID 30225715.

Functional connectivity describes statistical relationships between fluctuations in imaging signals across brain regions. These signals reflect changes in blood oxygenation associated with neural activity; they are not direct measurements of individual neurons firing or of a peptide binding to a receptor.

The study reported connectivity changes over this short observation window. That is a mechanistic observation worth distinguishing from a clinical outcome. It does not establish improved recall, sustained attention, learning or everyday functioning. A network can change without the change being beneficial, and a result minutes after exposure cannot establish a lasting effect.

The formulation and route also belong to the finding. This particular intranasal study is not evidence that any preparation bearing the Semax name produces the same exposure or response.

Selank was also studied through symptoms

A different kind of human investigation compared Selank with medazepam in 62 patients with generalized anxiety disorder and neurasthenia: 30 received Selank and 32 received medazepam. The investigators used clinical rating scales to assess symptoms. Primary study, PMID 18454096.

Unlike an imaging endpoint, a symptom scale directly addresses patients' reported or assessed clinical state. Nevertheless, an active-comparator study without a placebo group cannot separately quantify placebo-associated improvement. Similar observed responses would also not, by themselves, establish formal equivalence; that requires an appropriately designed and powered comparison. The abstract should not be treated as establishing a specific administration route or modern blinded, placebo-controlled confirmation.

Why separate treatment arms do not establish synergy

A 2020 imaging study involved 52 healthy participants in separate Semax, Selank and placebo arms. It examined functional connectivity, not a combined Semax–Selank intervention. Panikratova et al., 2020.

That distinction rules out using this study as evidence that the two compounds complement each other clinically. Demonstrating a combination advantage would require testing the combination against its individual components with a defined outcome—not simply placing two separate findings beside each other.

The useful interpretation is therefore compound-specific and endpoint-specific: Semax has been examined for short-term imaging changes, while Selank has also been evaluated through anxiety-related symptom ratings. Neither line of evidence turns the pair into an established cognitive-enhancement treatment. For the separate question of how route affects exposure, see how nasal peptide delivery works.